Setmelanotide: Imcivree for Rare Genetic Obesity
The first drug ever approved by the FDA for monogenic obesity — restoring the melanocortin-4 signal in patients whose hunger circuitry is broken at the genetic level. Not a GLP-1, not a Wegovy alternative.
How It Works
Setmelanotide binds and activates the melanocortin-4 receptor (MC4R) in the hypothalamus — the same receptor that POMC, PCSK1, and LEPR all normally signal to through α-MSH. When upstream genes are broken, the MC4R pathway goes silent and hunger never switches off. Setmelanotide rescues that signal directly, bypassing the broken step.
Phase 3 patient diaries showed large reductions in "most hunger" scores within weeks — patients reported feeling full for the first time. Weight loss follows reduced caloric intake, but the primary subjective effect is the disappearance of the hyperphagia that defines monogenic obesity.
The molecule has ~20-fold selectivity for MC4R over MC1R, but MC1R is still hit enough to cause skin darkening (hyperpigmentation) and new nevi in many patients — the predictable cosmetic side effect of any systemic melanocortin agonist.
Dosed once daily SC (adults: 3 mg; pediatric titration based on weight and tolerability). Multi-dose pen (10 mg/mL). Steady-state plasma levels reached in ~12 days. Half-life ~11 hours allows daily dosing without accumulation.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- FDA-approved for chronic weight management in patients ≥6 yr with biallelic POMC, PCSK1, or LEPR deficiency (2020), expanded to BBS in 2022 and to ages ≥2 yr in 2024.
- MC4R agonist — restores the melanocortin signal downstream of the genetic defect; not a GLP-1, not an appetite suppressant in the conventional sense.
- Phase 3 data: 80% of POMC/PCSK1 patients and 45% of LEPR patients achieved ≥10% body weight loss at 1 year (Clément 2020).
- Bardet-Biedl Phase 3 (Haqq 2022) showed ~32% of patients hit ≥10% weight loss at 52 weeks — modest but meaningful in a syndrome with limited options.
- Genetic testing is required before prescription — Rhythm Pharma sponsors a free testing program (Uncovering Rare Obesity) for clinicians.
- Common adverse effects: injection-site reactions (>90%), skin hyperpigmentation and new nevi (~50%), nausea, headache, and spontaneous penile erections.
- List price ~$300,000/year. Coverage is conditional on documented genetic diagnosis and is generally not available off-label.
- It is NOT approved or studied for general obesity, common polygenic obesity, or "stubborn" weight that resists diet — efficacy in those populations was never demonstrated.
- Long-term cardiovascular outcomes data does not yet exist — the FDA label requires monitoring of blood pressure and skin exams.
- Pregnancy and lactation safety has not been established; the label recommends contraception during treatment.
- Head-to-head comparisons against GLP-1 receptor agonists in BBS or monogenic obesity have not been run.
- Whether the new-nevi finding represents a long-term melanoma risk is unknown — full-body annual skin exams are recommended.
- No oral formulation exists; daily SC injection is the only route.
Frequently Asked Questions
What is setmelanotide and how is Imcivree different from a GLP-1?
Setmelanotide (brand name Imcivree, made by Rhythm Pharmaceuticals) is a melanocortin-4 receptor (MC4R) agonist. GLP-1 drugs like semaglutide slow gastric emptying and act on appetite via vagal and GLP-1R pathways. Setmelanotide directly fires the satiety receptor in the hypothalamus that is silent in patients with POMC, PCSK1, LEPR, or BBS gene defects. The two drug classes treat fundamentally different problems and are not interchangeable.
Who actually qualifies for Imcivree?
In the US, patients ≥2 years old (≥6 for non-BBS indications) with biallelic POMC, PCSK1, or LEPR deficiency confirmed by genetic testing, or with a clinical diagnosis of Bardet-Biedl syndrome. Genetic confirmation is the gating step — Rhythm sponsors a free no-charge testing program (Uncovering Rare Obesity / Rhythm in Action) for clinicians to identify candidates.
Does setmelanotide cause tanning like Melanotan II?
Yes — about half of patients in the Phase 3 trials developed darker skin, new freckles, or new moles from MC1R cross-activation. This is the same mechanism that makes Melanotan II tan the skin. Setmelanotide is more selective for MC4R, but the MC1R activation is still clinically obvious and requires annual skin exams. Patients with light skin pigment can see visibly darker skin within weeks.
How much does Imcivree cost?
List price is roughly $300,000 per year. Coverage by US commercial insurers and Medicaid is conditional on documented genetic diagnosis and prior authorization. Rhythm Pharmaceuticals operates a patient access program that handles benefits investigation, copay support, and prior auth assistance for qualifying patients.
Why is setmelanotide approved if only 32% of BBS patients lost ≥10%?
Bardet-Biedl syndrome has no other targeted therapy and patients face severe progressive obesity in childhood. A 32% response rate sounds modest in the context of GLP-1 trial language, but in an ultra-rare untreatable syndrome the FDA balanced the moderate effect size against the unmet need. Many responders had clinically dramatic reductions in hunger scores even when total weight loss was below 10%.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
Setmelanotide (Imcivree) is a prescription drug with serious side effects. It is approved only for specific rare genetic obesity indications and requires confirmed genetic testing.
Do not attempt to obtain or use this drug outside the FDA-approved indications. Speak with a board-certified endocrinologist or pediatric obesity specialist if you suspect monogenic obesity.